Health (PRISME)

  • Presentation
  • Activities
  • Members
  • Publications

The PRISME team is composed of physicists, biochemists, biologists and radiotherapists. We specialize in multidisciplinary research aimed at developing, optimizing and controlling innovative radiotherapies, whether it be hadrontherapy or therapies using radioactive ion-emitting elements or nanoparticles. These radiotherapies aim to improve the treatment of certain cancers by increasing the effect of ionizing radiation in the tumor while minimizing its harmful effects on healthy tissues.

Our multidisciplinary approach aims to quantify, understand and predict the effect of ionizing radiation on living organisms from processes induced at extremely short times (attosecond) at small scales (atomic nucleus) to long-term consequences (years) at the patient level.
We therefore design and carry out irradiation experiments on targets ranging from molecules or cells to small animals and patient samples (tumor, blood). These experiments feed an important part of our activity which consists in modeling the effects of radiation on living organisms.

One of the innovative techniques of radiotherapy is hadrontherapy, which is to send
an ion beam on the tumors to destroy them. We are working, in particular using simulations, data processing and predictions, to improve these systems by having on-line control over irradiation using dedicated detectors. These tools also have applications in imaging.

The activities can be divided into three research areas:

Axis 1 aims to develop simulations and detectors to control patient irradiation by detecting the particles emitted during hadrontherapy treatment. These developments also offer application prospects in the field of diagnostic imaging.

Axis 2 focuses on the development of multi-scale models and simulations to describe and predict the physical, chemical and biological processes induced by irradiation. It also develops irradiation and dosimetric control means for the measurement of radiobiological effects.

Axis 3 quantifies by experiment the effects induced by irradiation with molecular, cellular, multicellular, in-vitro or in-vivo systems. It focuses on the specificities of innovative radiotherapies and the personalization of care.

PERMANENTS:

NON-PERMANENTS:

- DOCTORANTS / DOCTORAL STUDENTS:

- CHERCHEURS NON-PERMANENTS / NON-PERMANENT RESEARCHERS:
544 documents

  • M. Cunha, E. Testa, M. Beuve, J. Balosso, A. Chaikh. Evaluation of the size of micrometric/nanometric dosimeters for use in radiotherapy and medical physics. ICTR-PHE 2016, Feb 2016, Genève, Switzerland. ⟨hal-01276322⟩
  • M. Cunha, C. Monini, E. Testa, M. Beuve. NanoxTM: A new multiscale theoretical framework to predict cell survival in the context of particle therapy. ICTR-PHE 2016, Feb 2016, Genève, Switzerland. ⟨hal-01276353⟩
  • A. Wozny, A. Lauret, Y. Saintigny, P. Battiston-Montagne, M. Beuve, et al.. HIF-1α plays a key role in the response of HNSCC cancer stem cells to photon and carbon ion exposures. ICTR-PHE 2016, Feb 2016, Genève, Switzerland. pp.S115. ⟨hal-01276470⟩
  • Jochen Krimmer, Denis Dauvergne, Etienne Testa. A beam hodoscope for ion therapy monitoring by means of secondary radiations. Wilhelm and Else Heraeus-Seminar Semiconductor detectors in astronomy, medicine, particle physics and photon science, Feb 2016, Bad Honnef, Germany. ⟨hal-01457896⟩
  • Shady Kotb, Alexandre Detappe, François Lux, Florence Appaix, Emmanuel L. Barbier, et al.. Gadolinium-Based Nanoparticles and Radiation Therapy for Multiple Brain Melanoma Metastases: Proof of Concept before Phase I Trial. Theranostics, 2016, 6 (3), pp.418-427. ⟨10.7150/thno.14018⟩. ⟨hal-01266945⟩
  • Cyrus Chargari, Karyn A. Goodman, Ibrahima Diallo, Jean-Baptiste Guy, Chloé Rancoule, et al.. Risk of second cancers in the era of modern radiation therapy: does the risk/benefit analysis overcome theoretical models?. Cancer and Metastasis Reviews, 2016, 35 (2), pp.277-288. ⟨10.1007/s10555-016-9616-2⟩. ⟨hal-01404955⟩
  • Alexis Vallard, Sophie Espenel, Jean-Baptiste Guy, Peng Diao, Yaoxiong Xia, et al.. Targeting stem cells by radiation: From the biological angle to clinical aspects . World Journal of Stem Cells, 2016, 8 (8), pp.243-250. ⟨10.4252/WJSC.v8.i8.243⟩. ⟨hal-01375903⟩
  • Nathalie Bonnin, Emma Armandy, Julien Carras, Sylvain Ferrandon, Priscillia Battiston-Montagne, et al.. MiR-422a promotes loco-regional recurrence by targeting NT5E/CD73 in head and neck squamous cell carcinoma. Oncotarget, 2016, 7 (28), pp.44023-44038. ⟨10.18632/oncotarget.9829⟩. ⟨hal-01376219⟩
  • Jean-Baptiste Guy, Chloé Rancoule, Benoîte Méry, Sophie Espenel, Anne-Sophie Wozny, et al.. Radiosensibilité et/ou résistance des cancers ORL : aspects biologiques. Bulletin du Cancer, 2016, 103 (1), pp.41-47. ⟨10.1016/j.bulcan.2015.10.016⟩. ⟨hal-01278015⟩
  • Anne-Sophie Wozny, Gersende Alphonse, Priscillia Battiston-Montagne, Stéphanie Simonet, Delphine Poncet, et al.. Influence of Dose Rate on the Cellular Response to Low- and High-LET Radiations. Frontiers in Oncology, 2016, 6 (58), ⟨10.3389/fonc.2016.00058⟩. ⟨hal-01376232⟩

Powered by HAL logo